Automatic prostate tracking and motion assessment in volumetric modulated arc therapy with an electronic portal imaging device - Abstract

PURPOSE: To assess the prostate intrafraction motion in volumetric modulated arc therapy treatments using cine megavoltage (MV) images acquired with an electronic portal imaging device (EPID).

METHODS AND MATERIALS: Ten prostate cancer patients were treated with volumetric modulated arc therapy using a Varian TrueBeam linear accelerator equipped with an EPID for acquiring cine MV images during treatment. Cine MV images acquisition was scheduled for single or multiple treatment fractions (between 1 and 8). A novel automatic fiducial detection algorithm that can handle irregular multileaf collimator apertures, field edges, fast leaf and gantry movement, and MV image noise and artifacts in patient anatomy was used. All sets of images (approximately 25,000 images in total) were analyzed to measure the positioning accuracy of implanted fiducial markers and assess the prostate movement.

RESULTS: Prostate motion can vary greatly in magnitude among different patients. Different motion patterns were identified, showing its unpredictability. The mean displacement and standard deviation of the intrafraction motion was generally less than 2.0 ± 2.0 mm in each of the spatial directions. In certain patients, however, the percentage of the treatment time in which the prostate is displaced more than 5 mm from its planned position in at least 1 spatial direction was 10% or more. The maximum prostate displacement observed was 13.3 mm.

CONCLUSION: Prostate tracking and motion assessment was performed with MV imaging and an EPID. The amount of prostate motion observed suggests that patients will benefit from its real-time monitoring. Megavoltage imaging can provide the basis for real-time prostate tracking using conventional linear accelerators.

Written by:
Azcona JD, Li R, Mok E, Hancock S, Xing L.   Are you the author?
Department of Radiation Oncology, Stanford University, Stanford, California, 94305; Division of Radiation Physics, Department of Oncology, Clínica Universidad de Navarra, 31080 Pamplona, Navarra, Spain.

Reference: Int J Radiat Oncol Biol Phys. 2013 Apr 19. pii: S0360-3016(13)00268-X.
doi: 10.1016/j.ijrobp.2013.03.007

PubMed Abstract
PMID: 23608236 Prostate Cancer Section